 <h1>Estreva Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>estradiol</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about estradiol. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Estreva.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to estradiol: vaginal capsule liquid filled, vaginal cream, vaginal insert extended release, vaginal tablet</i></p><p>Other dosage forms:</p><ul><li>transdermal gel/jelly, transdermal patch extended release, transdermal spray</li></ul><h3>Warning</h3><p class="blackboxWarning-title">Vaginal route (Insert, Extended Release; Cream)</p><p>Estrogens increase the risk of endometrial cancer; monitor for abnormal vaginal bleeding. Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. Increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) have been reported. An increased risk of developing probable dementia in postmenopausal women 65 years of age or older has also been reported in women receiving estrogen alone or estrogen combined with progestins. Risks should be assumed to be similar for other doses, combinations, and dosage forms of estrogens and progestins. Estrogens, with or without progestins, should be prescribed at the lowest effective doses and for the shortest duration possible.</p><p class="blackboxWarning-title">Vaginal route (Insert, Extended Release)</p><p>Use of unopposed estrogens increases the risk of endometrial cancer, while addition of a progestin decreases the risk of endometrial hyperplasia. Rule out malignancy if abnormal vaginal bleeding develops. Do not use estrogen alone or in combination with progestin to prevent cardiovascular disease or dementia. There is an increased risk of cardiovascular disorders (ie, DVT, pulmonary embolism, stroke, myocardial infarction) with combination therapy in women 50 years or older, and an increased risk of dementia in women 65 years or older with estrogen monotherapy or combination therapy. Combination therapy also increases the risk of invasive breast cancer. Prescribe estrogens with or without progestins at the lowest effective dose and for the shortest duration consistent with risks and treatment goals.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, estradiol (the active ingredient contained in Estreva) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking estradiol:</p><p>
<i>Less common</i>
</p><ul>
<li>Vaginal yeast infection</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Change in vaginal discharge</li>
<li>clear or bloody discharge from the nipple</li>
<li>decrease in the amount of urine</li>
<li>dimpling of the breast skin</li>
<li>fast heartbeat</li>
<li>fever</li>
<li>hives, itching, or rash</li>
<li>hoarseness</li>
<li>inverted nipple</li>
<li>irritation</li>
<li>joint pain, stiffness, or swelling</li>
<li>lump in the breast or under the arm</li>
<li>noisy, rattling breathing</li>
<li>pain or feeling of pressure in the pelvis</li>
<li>pain, redness, or swelling in the arm or leg</li>
<li>persistent crusting or scaling of the nipple</li>
<li>redness of the skin</li>
<li>redness or swelling of the breast</li>
<li>sore on the skin of the breast that does not heal</li>
<li>swelling of the eyelids, face, fingers, lips, hands, feet, or lower legs</li>
<li>tightness in the chest</li>
<li>troubled breathing at rest</li>
<li>troubled breathing or swallowing</li>
<li>vaginal bleeding</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking estradiol:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Dizziness</li>
<li>drowsiness</li>
<li>nausea</li>
<li>stomach pain</li>
<li>tenderness of the breasts</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of estradiol may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>headache</li>
<li>itching or pain of the vagina or genital area</li>
<li>thick, white vaginal discharge with mild or no odor</li>
<li>weight gain</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Body aches or pain</li>
<li>chills</li>
<li>cough</li>
<li>diarrhea</li>
<li>ear congestion</li>
<li>loss of voice</li>
<li>nasal congestion</li>
<li>runny nose</li>
<li>sneezing</li>
<li>sore throat</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Feeling sad or empty</li>
<li>headache, severe and throbbing</li>
<li>irritability</li>
<li>lack of appetite</li>
<li>tiredness</li>
<li>trouble concentrating</li>
<li>trouble sleeping</li>
<li>welts</li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to estradiol: compounding powder, intramuscular solution, oral tablet, transdermal emulsion, transdermal film extended release, transdermal gel, transdermal spray, vaginal ring</i></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Breast pain (29%)</p>
<p><b>Common</b> (1% to 10%): Vulvovaginal pruritus, leukorrhea, vaginal hemorrhage, vaginal discharge, vaginal discomfort, menopause symptoms, breakthrough bleeding or spotting, dysmenorrhea, breast swelling, menorrhagia, metrorrhagia, endometrial hyperplasia</p>
<p><b>Uncommon</b> (0.1% to 1%): Urinary problems</p>
<p><b>Rare</b> (less than 0.1%): Galactorrhea</p>
<p><b>Postmarketing reports</b>: Vaginal irritation, vaginal pain, genital pruritus, changes in bleeding pattern, pelvic pain, breast tenderness, vaginal ulceration, uterine fibroids<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Abdominal pain (16%),</p>
<p><b>Common</b> (1% to 10%): Flatulence, nausea, diarrhea</p>
<p><b>Uncommon</b> (0.1% to 1%): Vomiting</p>
<p><b>Postmarketing reports</b>: Abdominal distension<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (11%), arthralgia (11%)</p>
<p><b>Common</b> (1% to 10%): Leg cramps<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Varicose veins, cardiac symptoms (e.g.  palpitations)</p>
<p><b>Uncommon</b> (0.1% to 1%): Hot flush, hypertension, venous thromboembolic disease</p>
<p><b>Rare</b> (less than 0.1%): Arterial hypertension</p>
<p><b>Postmarketing reports</b>: Deep vein thrombosis, changes in blood pressure<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (18%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Vertigo, migraine</p>
<p><b>Rare</b> (less than 0.1%): Aggravation of epilepsy</p>
<p><b>Postmarketing reports</b>: Migraine aggravated, paresthesia, dizziness<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Benign breast neoplasm, increased volume of uterine leiomyoma</p>
<p><b>Postmarketing reports</b>: Endometrial cancer, breast cancer<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pain (11%)</p>
<p><b>Common</b> (1% to 10%): Edema</p>
<p><b>Uncommon</b> (0.1% to 1%): Weight increased, asthenia</p>
<p><b>Postmarketing reports</b>: Drug ineffectiveness, blood estrogen increase, fatigue, exacerbation of hereditary angioedema<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression</p>
<p><b>Uncommon</b> (0.1% to 1%): Sleep disorders, nervousness, mood swings</p>
<p><b>Rare</b> (less than 0.1%): Change in libido</p>
<p><b>Postmarketing reports</b>: Vaginismus, insomnia, anxiety, irritability<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Pruritus</p>
<p><b>Uncommon</b> (0.1% to 1%): Rash </p>
<p><b>Rare</b> (less than 0.1%): Skin discoloration, acne</p>
<p><b>Postmarketing reports</b>: Urticaria, erythematous or pruritic rash, alopecia, hyperhidrosis, night sweats, contact dermatitis, eczema<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Vision abnormal NOS</p>
<p><b>Postmarketing reports</b>: Visual disturbances, contact lens intolerance<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Rare</b> (less than 0.1%): Liver function tests abnormalities</p>
<p><b>Postmarketing reports</b>: Cholestatic jaundice<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Rare</b> (less than 0.1%): Glucose intolerance</p>
<p><b>Postmarketing reports</b>: Fluid retention<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (less than 0.1%): Anaphylactic reaction (with a past history of allergic reaction)</p>
<p><b>Postmarketing reports</b>: Anaphylactic reactions, hypersensitivity<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infection (17%)</p>
<p><b>Common</b> (1% to 10%): Vulvovaginal mycotic infection, pharyngitis, rhinitis, sinusitis, moniliasis genital </p>
<p><b>Uncommon</b> (0.1% to 1%): Vaginitis/vaginal candidosis<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Skin irritation (topical gel)</p>
<p><b>Postmarketing reports</b>: Application site reaction<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Estradiol Vaginal Insert (estradiol topical)." Teva Pharmaceuticals USA, North Wales, PA. </p><p id="ref_2">2. Julian TM "Pseudoincontinence secondary to unopposed estrogen replacement in the surgically castrate premenopausal female." Obstet Gynecol 70 (1987): 382-3</p><p id="ref_3">3. "Product Information. Climara (estradiol)." Berlex, Richmond, CA. </p><p id="ref_4">4. Nash HA, AlvarezSanchez F, Mishell DR, Fraser IS, Maruo T, Harmon TM "Estradiol-delivering vaginal rings for hormone replacement therapy." Am J Obstet Gynecol 181 (1999): 1400-6</p><p id="ref_5">5. "Product Information. Estrace (estradiol)." Warner Chilcott Laboratories, Rockaway, NJ. </p><p id="ref_6">6. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_7">7. Auerbach R, Mittal K, Schwartz PE "Estrogen and progestin receptors in an ovarian ependymoma." Obstet Gynecol 71 (1988): 1043-5</p><p id="ref_8">8. "Product Information. Yuvafem (estradiol topical)." AvKare Inc, Pulaski, TN. </p><p id="ref_9">9. Boston Collaborative Drug Surveilance Program "Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy." N Engl J Med 290 (1974): 15-9</p><p id="ref_10">10. Jick H, Dinan B, Rothman KJ "Noncontraceptive estrogens and nonfatal myocardial infarction." JAMA 239 (1978): 1407-8</p><p id="ref_11">11. Barrett-Connor E, Wingard DL, Criqui MH "Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited." JAMA 261 (1989): 1095-2100</p><p id="ref_12">12. Bui MN,  Arai AE,  Hathaway L,  Waclawiw MA,  Csako G,  Cannon RO 3rd "Effect of hormone replacement therapy on carotid arterial compliance in healthy postmenopausal women." Am J Cardiol 90 (2002): 82-5</p><p id="ref_13">13. Belchetz PE "Hormonal treatment of postmenopausal women." N Engl J Med 330 (1994): 1062-71</p><p id="ref_14">14. Crane MG, Harris JJ "Estrogens and hypertension: effect of discontinuing estrogens on blood pressure, exchangeable sodium, and the renin-aldosterone system." Am J Med Sci 276 (1978): 33-55</p><p id="ref_15">15. Barrett-Connor E, Bush TL "Estrogen and coronary heart disease in women." JAMA 265 (1991): 1861-7</p><p id="ref_16">16. Rosenberg L, Slone D, Shapiro S, Kaufman D, Stolley PD, Miettinen OS "Noncontraceptive estrogens and myocardial infarction in young women." JAMA 244 (1980): 339-42</p><p id="ref_17">17. Stampfer MJ, Colditz GA, Willett WC, et al. "Postmenopausal estrogen and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study." N Engl J Med 325 (1991): 756-62</p><p id="ref_18">18. Collins P, Beale CM, Rosano GMC "Oestrogen as a calcium channel blocker." Eur Heart J 17 ( Suppl (1996): 27-31</p><p id="ref_19">19. Schwartz J, Freeman R, Frishman W "Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women." J Clin Pharmacol 35 (1995): 1-16</p><p id="ref_20">20. Crane MG, Harris JJ, Winsor W 3d "Hypertension, oral contraceptive agents, and conjugated estrogens." Ann Intern Med 74 (1971): 13-21</p><p id="ref_21">21. Grady D, Rubin SM, Petiti DB, et al. "Hormone therapy to prevent disease and prolong life in postmenopausal women." Ann Intern Med 117 (1992): 1016-36</p><p id="ref_22">22. The Writing Group for the PEPI Trial "Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial." JAMA 273 (1995): 199-208</p><p id="ref_23">23. Wren BG, Routledge DA "Blood pressure changes: oestrogens in climacteric women." Med J Aust 2 (1981): 528-31</p><p id="ref_24">24. Cohen L, Coxwell WL, Melchione T, Koltun W, Gibson E, Gupta N, Roberts M "Low-dose 17-beta estradiol matrix transdermal system in the treatment of moderate-to-severe hot flushes in postmenopausal women." Curr Ther Res Clin Exp 60 (1999): 534-47</p><p id="ref_25">25. Steiger MJ, Quinn NP "Hormone replacement therapy induced chorea." BMJ 302 (1991): 762</p><p id="ref_26">26. Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S "Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study." Am J Epidemiol 134 (1991): 1386-95</p><p id="ref_27">27. Colditz GA, Hankinson SE, Hunter DJ, et al. "The use of estrogens and progestins and the risk of breast cancer in postmenopausal women." N Engl J Med 332 (1995): 1589-93</p><p id="ref_28">28. Kaufman DW, Palmer JR, de Mouzon J, Rosenberg L, Stolley PD, Warshauer ME, Zauber AG, Shapiro S "Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study." Am J Epidemiol 134 (1991): 1375-85</p><p id="ref_29">29. Obrink A, Bunne G, Collen J, Tjernberg B "Endometrial cancer and exogenous estrogens." Acta Obstet Gynecol Scand 58 (1979): 123</p><p id="ref_30">30. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C "The risk of breast cancer after estrogen and estrogen-progestin replacement." N Engl J Med 321 (1989): 293-7</p><p id="ref_31">31. Gapstur SM, Morrow M, Sellers TA "Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa women's health study." JAMA 281 (1999): 2091-7</p><p id="ref_32">32. Antunes CM, Strolley PD, Rosenshein NB, Davies JL, Tonascia JA, Brown C, Burnett L, Rutledge A, Pokempner M, Garcia R "Endometrial cancer and estrogen use. Report of a large case-control study." N Engl J Med 300 (1979): 9-13</p><p id="ref_33">33. Gordon J, Reagan JW, Finkle WD, Ziel HK "Estrogen and endometrial carcinoma. An independent pathology review supporting original risk estimate." N Engl J Med 297 (1977): 570-1</p><p id="ref_34">34. The Writing Group for the PEPI Trial "Effects of hormone replacement therapy on endometrial histology in postmenopausal women." JAMA 275 (1996): 370-5</p><p id="ref_35">35. Gray LA Sr, Christopherson WM, Hoover RN "Estrogens and endometrial carcinoma." Obstet Gynecol 49 (1977): 385-9</p><p id="ref_36">36. Thomas DB, Persing JP, Hutchinson WB "Exogenous estrogens and other risk factors for breast cancer in women with benign breast diseases." J Natl Cancer Inst 69 (1982): 1017-25</p><p id="ref_37">37. Spengler RF, Clarke EA, Woolever CA, Newman AM, Osborn RW "Exogenous estrogens and endometrial cancer: a case-control study and assessment of potential biases." Am J Epidemiol 114 (1981): 497-506</p><p id="ref_38">38. Oppenheim G "A case of rapid mood cycling with estrogen: implications for therapy." J Clin Psychiatry 45 (1984): 34-5</p><p id="ref_39">39. Conter RL, Longmire WP Jr "Recurrent hepatic hemangiomas. Possible association with estrogen therapy." Ann Surg 207 (1988): 115-9</p><p id="ref_40">40. Aldinger K, Ben-Menachem Y, Whalen G "Focal nodular hyperplasia of the liver associated with high-dosage estrogens." Arch Intern Med 137 (1977): 357-9</p><p id="ref_41">41. Molitch ME, Oill P, Odell WD "Massive hyperlipemia during estrogen therapy." JAMA 227 (1974): 522-5</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Estreva (estradiol)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: estrogens</li>
<li>FDA Alerts (2)</li>
</ul>
<h3>Consumer resources</h3>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Estrace, Vivelle-Dot, Climara, Estradiol Patch, ... +17 more</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Postmenopausal Symptoms</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to estradiol: compounding powder, intramuscular solution, oral tablet, transdermal emulsion, transdermal film extended release, transdermal gel, transdermal spray, vaginal ring</i></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Breast pain (29%)</p><p><b>Common</b> (1% to 10%): Vulvovaginal pruritus, leukorrhea, vaginal hemorrhage, vaginal discharge, vaginal discomfort, menopause symptoms, breakthrough bleeding or spotting, dysmenorrhea, breast swelling, menorrhagia, metrorrhagia, endometrial hyperplasia</p><p><b>Uncommon</b> (0.1% to 1%): Urinary problems</p><p><b>Rare</b> (less than 0.1%): Galactorrhea</p><p><b>Postmarketing reports</b>: Vaginal irritation, vaginal pain, genital pruritus, changes in bleeding pattern, pelvic pain, breast tenderness, vaginal ulceration, uterine fibroids<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Abdominal pain (16%),</p><p><b>Common</b> (1% to 10%): Flatulence, nausea, diarrhea</p><p><b>Uncommon</b> (0.1% to 1%): Vomiting</p><p><b>Postmarketing reports</b>: Abdominal distension<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (11%), arthralgia (11%)</p><p><b>Common</b> (1% to 10%): Leg cramps<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Varicose veins, cardiac symptoms (e.g.  palpitations)</p><p><b>Uncommon</b> (0.1% to 1%): Hot flush, hypertension, venous thromboembolic disease</p><p><b>Rare</b> (less than 0.1%): Arterial hypertension</p><p><b>Postmarketing reports</b>: Deep vein thrombosis, changes in blood pressure<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (18%)</p><p><b>Uncommon</b> (0.1% to 1%): Vertigo, migraine</p><p><b>Rare</b> (less than 0.1%): Aggravation of epilepsy</p><p><b>Postmarketing reports</b>: Migraine aggravated, paresthesia, dizziness<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Benign breast neoplasm, increased volume of uterine leiomyoma</p><p><b>Postmarketing reports</b>: Endometrial cancer, breast cancer<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pain (11%)</p><p><b>Common</b> (1% to 10%): Edema</p><p><b>Uncommon</b> (0.1% to 1%): Weight increased, asthenia</p><p><b>Postmarketing reports</b>: Drug ineffectiveness, blood estrogen increase, fatigue, exacerbation of hereditary angioedema<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression</p><p><b>Uncommon</b> (0.1% to 1%): Sleep disorders, nervousness, mood swings</p><p><b>Rare</b> (less than 0.1%): Change in libido</p><p><b>Postmarketing reports</b>: Vaginismus, insomnia, anxiety, irritability<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Pruritus</p><p><b>Uncommon</b> (0.1% to 1%): Rash </p><p><b>Rare</b> (less than 0.1%): Skin discoloration, acne</p><p><b>Postmarketing reports</b>: Urticaria, erythematous or pruritic rash, alopecia, hyperhidrosis, night sweats, contact dermatitis, eczema<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Vision abnormal NOS</p><p><b>Postmarketing reports</b>: Visual disturbances, contact lens intolerance<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Rare</b> (less than 0.1%): Liver function tests abnormalities</p><p><b>Postmarketing reports</b>: Cholestatic jaundice<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Rare</b> (less than 0.1%): Glucose intolerance</p><p><b>Postmarketing reports</b>: Fluid retention<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (less than 0.1%): Anaphylactic reaction (with a past history of allergic reaction)</p><p><b>Postmarketing reports</b>: Anaphylactic reactions, hypersensitivity<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infection (17%)</p><p><b>Common</b> (1% to 10%): Vulvovaginal mycotic infection, pharyngitis, rhinitis, sinusitis, moniliasis genital </p><p><b>Uncommon</b> (0.1% to 1%): Vaginitis/vaginal candidosis<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Skin irritation (topical gel)</p><p><b>Postmarketing reports</b>: Application site reaction<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Estradiol Vaginal Insert (estradiol topical)." Teva Pharmaceuticals USA, North Wales, PA. </p><p id="ref_2">2. Julian TM "Pseudoincontinence secondary to unopposed estrogen replacement in the surgically castrate premenopausal female." Obstet Gynecol 70 (1987): 382-3</p><p id="ref_3">3. "Product Information. Climara (estradiol)." Berlex, Richmond, CA. </p><p id="ref_4">4. Nash HA, AlvarezSanchez F, Mishell DR, Fraser IS, Maruo T, Harmon TM "Estradiol-delivering vaginal rings for hormone replacement therapy." Am J Obstet Gynecol 181 (1999): 1400-6</p><p id="ref_5">5. "Product Information. Estrace (estradiol)." Warner Chilcott Laboratories, Rockaway, NJ. </p><p id="ref_6">6. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_7">7. Auerbach R, Mittal K, Schwartz PE "Estrogen and progestin receptors in an ovarian ependymoma." Obstet Gynecol 71 (1988): 1043-5</p><p id="ref_8">8. "Product Information. Yuvafem (estradiol topical)." AvKare Inc, Pulaski, TN. </p><p id="ref_9">9. Boston Collaborative Drug Surveilance Program "Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy." N Engl J Med 290 (1974): 15-9</p><p id="ref_10">10. Jick H, Dinan B, Rothman KJ "Noncontraceptive estrogens and nonfatal myocardial infarction." JAMA 239 (1978): 1407-8</p><p id="ref_11">11. Barrett-Connor E, Wingard DL, Criqui MH "Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited." JAMA 261 (1989): 1095-2100</p><p id="ref_12">12. Bui MN,  Arai AE,  Hathaway L,  Waclawiw MA,  Csako G,  Cannon RO 3rd "Effect of hormone replacement therapy on carotid arterial compliance in healthy postmenopausal women." Am J Cardiol 90 (2002): 82-5</p><p id="ref_13">13. Belchetz PE "Hormonal treatment of postmenopausal women." N Engl J Med 330 (1994): 1062-71</p><p id="ref_14">14. Crane MG, Harris JJ "Estrogens and hypertension: effect of discontinuing estrogens on blood pressure, exchangeable sodium, and the renin-aldosterone system." Am J Med Sci 276 (1978): 33-55</p><p id="ref_15">15. Barrett-Connor E, Bush TL "Estrogen and coronary heart disease in women." JAMA 265 (1991): 1861-7</p><p id="ref_16">16. Rosenberg L, Slone D, Shapiro S, Kaufman D, Stolley PD, Miettinen OS "Noncontraceptive estrogens and myocardial infarction in young women." JAMA 244 (1980): 339-42</p><p id="ref_17">17. Stampfer MJ, Colditz GA, Willett WC, et al. "Postmenopausal estrogen and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study." N Engl J Med 325 (1991): 756-62</p><p id="ref_18">18. Collins P, Beale CM, Rosano GMC "Oestrogen as a calcium channel blocker." Eur Heart J 17 ( Suppl (1996): 27-31</p><p id="ref_19">19. Schwartz J, Freeman R, Frishman W "Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women." J Clin Pharmacol 35 (1995): 1-16</p><p id="ref_20">20. Crane MG, Harris JJ, Winsor W 3d "Hypertension, oral contraceptive agents, and conjugated estrogens." Ann Intern Med 74 (1971): 13-21</p><p id="ref_21">21. Grady D, Rubin SM, Petiti DB, et al. "Hormone therapy to prevent disease and prolong life in postmenopausal women." Ann Intern Med 117 (1992): 1016-36</p><p id="ref_22">22. The Writing Group for the PEPI Trial "Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial." JAMA 273 (1995): 199-208</p><p id="ref_23">23. Wren BG, Routledge DA "Blood pressure changes: oestrogens in climacteric women." Med J Aust 2 (1981): 528-31</p><p id="ref_24">24. Cohen L, Coxwell WL, Melchione T, Koltun W, Gibson E, Gupta N, Roberts M "Low-dose 17-beta estradiol matrix transdermal system in the treatment of moderate-to-severe hot flushes in postmenopausal women." Curr Ther Res Clin Exp 60 (1999): 534-47</p><p id="ref_25">25. Steiger MJ, Quinn NP "Hormone replacement therapy induced chorea." BMJ 302 (1991): 762</p><p id="ref_26">26. Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S "Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study." Am J Epidemiol 134 (1991): 1386-95</p><p id="ref_27">27. Colditz GA, Hankinson SE, Hunter DJ, et al. "The use of estrogens and progestins and the risk of breast cancer in postmenopausal women." N Engl J Med 332 (1995): 1589-93</p><p id="ref_28">28. Kaufman DW, Palmer JR, de Mouzon J, Rosenberg L, Stolley PD, Warshauer ME, Zauber AG, Shapiro S "Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study." Am J Epidemiol 134 (1991): 1375-85</p><p id="ref_29">29. Obrink A, Bunne G, Collen J, Tjernberg B "Endometrial cancer and exogenous estrogens." Acta Obstet Gynecol Scand 58 (1979): 123</p><p id="ref_30">30. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C "The risk of breast cancer after estrogen and estrogen-progestin replacement." N Engl J Med 321 (1989): 293-7</p><p id="ref_31">31. Gapstur SM, Morrow M, Sellers TA "Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa women's health study." JAMA 281 (1999): 2091-7</p><p id="ref_32">32. Antunes CM, Strolley PD, Rosenshein NB, Davies JL, Tonascia JA, Brown C, Burnett L, Rutledge A, Pokempner M, Garcia R "Endometrial cancer and estrogen use. Report of a large case-control study." N Engl J Med 300 (1979): 9-13</p><p id="ref_33">33. Gordon J, Reagan JW, Finkle WD, Ziel HK "Estrogen and endometrial carcinoma. An independent pathology review supporting original risk estimate." N Engl J Med 297 (1977): 570-1</p><p id="ref_34">34. The Writing Group for the PEPI Trial "Effects of hormone replacement therapy on endometrial histology in postmenopausal women." JAMA 275 (1996): 370-5</p><p id="ref_35">35. Gray LA Sr, Christopherson WM, Hoover RN "Estrogens and endometrial carcinoma." Obstet Gynecol 49 (1977): 385-9</p><p id="ref_36">36. Thomas DB, Persing JP, Hutchinson WB "Exogenous estrogens and other risk factors for breast cancer in women with benign breast diseases." J Natl Cancer Inst 69 (1982): 1017-25</p><p id="ref_37">37. Spengler RF, Clarke EA, Woolever CA, Newman AM, Osborn RW "Exogenous estrogens and endometrial cancer: a case-control study and assessment of potential biases." Am J Epidemiol 114 (1981): 497-506</p><p id="ref_38">38. Oppenheim G "A case of rapid mood cycling with estrogen: implications for therapy." J Clin Psychiatry 45 (1984): 34-5</p><p id="ref_39">39. Conter RL, Longmire WP Jr "Recurrent hepatic hemangiomas. Possible association with estrogen therapy." Ann Surg 207 (1988): 115-9</p><p id="ref_40">40. Aldinger K, Ben-Menachem Y, Whalen G "Focal nodular hyperplasia of the liver associated with high-dosage estrogens." Arch Intern Med 137 (1977): 357-9</p><p id="ref_41">41. Molitch ME, Oill P, Odell WD "Massive hyperlipemia during estrogen therapy." JAMA 227 (1974): 522-5</p><h2>More about Estreva (estradiol)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: estrogens</li>
<li>FDA Alerts (2)</li>
</ul><h3>Consumer resources</h3><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Postmenopausal Symptoms</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>